Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133987 | 0.81 | LMNA (0.39) | — | |
| SCHEMBL1200148 | 0.81 | LIPG (0.44) | LIPGLPLHIF1ADGAT1PRMT5 | |
| SCHEMBL1199795 | 0.77 | HIF1A (0.40) | LIPGLPLHIF1ADGAT1F2 | |
| SCHEMBL1199769 | 0.76 | CA1 (0.41) | LIPGLPLHIF1ADGAT1F2 | |
| SCHEMBL13667940 | 0.76 | CYP19A1 (0.32) | ALDH1A1HDAC4MEF2DCYP19A1 | |
| SCHEMBL552268 | 0.74 | ALDH1A1 (0.51) | LIPGLPLALDH1A1 | |
| SCHEMBL2282683 | 0.72 | MAPK14 (0.45) | LIPGLPLHIF1A | |
| SCHEMBL2282699 | 0.72 | MAPK14 (0.45) | LIPGLPLHIF1A | |
| SCHEMBL2280780 | 0.72 | LIPG (0.39) | LIPGLPLHIF1A | |
| SCHEMBL2280542 | 0.72 | MAPK14 (0.47) | LIPGLPLHIF1APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2285797-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | Chroma Therapeutics Ltd. (GB) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009130475-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD., (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130475-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD., (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | IKBKE, CSNK1A1, CSNK1E | LIPG 2385/4885LPL 2464/4885HIF1A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.